By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Life Care NewsLife Care NewsLife Care News
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
Search
Technology
  • Advertise
  • Advertise
Health
Entertainment
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved.
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Reading: Mycotopia Therapies Inc. Announces Name Change to AIBiotics, Inc. and Symbol Change to AIBT
Share
Notification Show More
Font ResizerAa
Life Care NewsLife Care News
Font ResizerAa
  • Education
  • Automobile
  • Entertainment
  • News
  • Tech
  • Sports
Search
  • Home
  • Home
    • Home 1
    • Default Home 5
  • Categories
  • Categories
    • Tech
    • Entertainment
    • Automobile
    • Sports
    • Education
    • News
    • Health
  • Bookmarks
  • Bookmarks
  • More Foxiz
    • Sitemap
  • More Foxiz
    • Sitemap
Follow US
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Tech

Mycotopia Therapies Inc. Announces Name Change to AIBiotics, Inc. and Symbol Change to AIBT

GlobeNews Wire
Last updated: 01/02/2025 11:57 AM
GlobeNews Wire
Share
5 Min Read
Mycotopia Therapies Inc. Announces Name Change to AIBiotics, Inc. and Symbol Change to AIBT
SHARE
Mycotopia Therapies Inc. Announces Name Change to AIBiotics, Inc. and Symbol Change to AIBT

MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) — Mycotopia Therapies Inc. dba AIBotics (“AIBotics” or the “Company”) (OTC: TPIA) and a wholly owned subsidiary of Ehave (OTC: EHVVF), a developer and manager of companies and technologies that can be enhanced through artificial intelligence (AI) and robotics, today announced that FINRA has approved its request for a corporate name and stock symbol change under FINRA Rule 6490.

  • New Name: Aibotics Inc.
  • New Symbol: AIBT
  • Current CUSIP will remain the same: 62846W107
  • Daily list announcement date: 01/31/2025
  • Market effective date: 02/03/2025

AIBiotics develops and manages companies and technologies that integrate artificial intelligence (AI) and robotics to enhance innovation and efficiency across multiple industries. The Company focuses on identifying, developing, and scaling businesses that benefit from automation, machine learning, and advanced robotics, driving transformative solutions in healthcare, manufacturing, logistics, and beyond. By leveraging AI-driven insights and automation, AIBiotics aims to accelerate growth, improve operational performance, and create next-generation technologies that redefine industry standards.

AIBiotics announced on January 29, 2025, that the Company signed a letter of intent to acquire 100% of the capital stock of DigiTrax Entertainment Inc. (DigiTrax), an AI-driven leader in innovative music technology solutions. The transaction, valued at $40 million, includes seven U.S. patents in music AI, a $9 million music catalog, and licensing agreements with leading publishers.

About AIBiotics

AIBotics leverages AI and robotics to develop innovative solutions that address real-world challenges. Its flagship products include the Phill Robot™, an AI-powered massage robot that delivers spa-quality care with IoT integration, and Milkyway, a smart refrigerator that simplifies breast milk storage with automated organization and app connectivity.

For more information on AIBiotics, visit our website at https://www.aibotics.ai and our Indiegogo page at https://www.indiegogo.com/projects/phill-robot-world-s-1st-ai-powered-massage-robot#/.

Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of applicable securities legislation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions, opinions and estimates of management and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the U.S. Food and Drug Administration and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise, except as required by applicable law.

For Media and Investor Relations, please contact:

David L. Kugelman
(866) 692-6847 Toll Free – U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com

You Might Also Like

Best Cam Sites for Live Shows – Greenbot Announces Strategic Collaboration

New Global Survey Seeks Insights on Climate and Health

IOC and Allianz agree extension of Worldwide Olympic and Paralympic Partnership

Inaugural International MICE Summit (IMS) Convenes to Drive Business Events Sector’s Future in Saudi Arabia, Fastest-Growing G20 MICE Market

Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

TAGGED:aibioticsaiboticsaibtaidrivenannouncedannouncesartificialautomationchangecompaniescompanydbadigitraxfinraglobeincintelligencejanmiamimillionMusicmycotopianamenewswireotcownedroboticssolutionsstocksubsidiarysymboltechnologiestherapiestpiauncategorizedwholly

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Annovis Bio, Inc. Announces Proposed Public Offering Annovis Bio, Inc. Announces Proposed Public Offering
Next Article Nokia Corporation: Repurchase of own shares on 31.01.2025 Nokia Corporation: Repurchase of own shares on 31.01.2025

Stay Connected

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
Google NewsFollow
LinkedInFollow
MediumFollow
- Advertisement -

Latest News

MannKind to Highlight Data from Recent Pediatric and Adult Studiesof Inhaled Insulin (Afrezza) at American Diabetes Associations85th Scientific Sessions in Chicago, June 20-23
MannKind to Highlight Data from Recent Pediatric and Adult Studiesof Inhaled Insulin (Afrezza) at American Diabetes Associations85th Scientific Sessions in Chicago, June 20-23
Health 10/06/2025
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Health 10/06/2025
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Health 10/06/2025
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
Health 10/06/2025
//

We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Quick Link

  • About Us
  • Contact Us
  • Editorial Guidelines
  • Privacy Policy
  • Terms and Conditions

Top Categories

  • Automobile
  • Education
  • Entertainment
  • Health
  • News
  • Sports
  • Tech

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Life Care NewsLife Care News
Follow US
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?